Novel Oncology Therapies Require Innovative Methods in Oncology Modeling
May 16, 2023 |
Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.
Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.
Health technology assessment (HTA) agencies have long required evidence of long-term survival and lifetime estimates of quality of life before they will approve new treatments. Health economics and outcomes research analysts have relied on standard parametric models to extrapolate overall survival rates from clinical trial data to estimate quality of life.
This traditional approach identifies the statistical models that best fit the available data and then uses these models to predict outcomes over the lifetime. It worked well for traditional cancer treatments, including chemotherapy. However, many new oncology drugs have a different mechanism of action—including the possibility of delayed and prolonged response to treatment and, potentially, cure—which may not be accurately represented by these traditional models.
Applying standard models to novel oncology therapies may lead to inaccurate estimates of survival and/or quality-of-life benefits, which could cause HTA agencies to reject beneficial treatments. For patients to access potentially lifesaving medications, analysts need to use more sophisticated modeling methods that can accommodate the potentially complex hazard patterns associated with these treatments.
Choosing an oncology modeling method
Newer methods and techniques may better capture the potential value of innovative oncology treatments.
The appropriate modeling method can provide the foundation for an accurate assessment of the benefits associated with novel oncology therapies—a crucial step in gaining regulatory approval and getting treatment to those who need it. However, determining which model to use can be challenging.
In January 2020, the National Institute for Health and Care Excellence, Decision Support Unit issued Technical Support Document 21 (TSD 21), a guide to flexible methods for survival analysis. This document suggested some innovative modeling approaches, including cure models, mixture modeling, piecewise models and landmark approaches, and encouraged careful consideration of the tradeoff between short-term fit versus long-term assumptions. These newer methods aim to more accurately estimate the value of new drugs in terms of cost, life years and quality of life.
TSD 21, however, did not specify when—or under which circumstances—specific models should be used.
At present, guidance is limited as to when flexible models should be considered, and which might be most appropriate for a particular data set. An advisory board of seven international experts with in-depth knowledge of survival analysis and health technology assessment collaborated over the summer of 2021 to produce an algorithm that can be used to inform selection of flexible survival oncology models.
The algorithm, which consists of eight steps and four questions, was published in Value in Health journal in August 2022. It provides a systematic, evidence-based approach to justify the selection of extrapolation models for immunotherapeutic cancer medications, and, if followed, should reduce the risk of selecting inappropriate models that may underestimate the benefit of novel treatments.
Oncology modeling continues to play a vital role in determining (and demonstrating) the value of new cancer treatments, but traditional methods aren’t a good fit for new drugs that have prolonged responses. Flexible extrapolation models offer a better estimate of the value of new drugs. They offer cost-effective analyses of cancer immunotherapies and other innovative oncology therapies.
At OPEN Health, we use advanced survival modeling techniques as needed to demonstrate value. Our multidisciplinary teams have deep knowledge of oncology modeling and routinely help pharmaceutical companies navigate health technology assessments and joint clinical assessments.
Learn more about OPEN Health: https://www.openhealthgroup.com/
This content was provided by OPEN Health
Company Details
Latest Content from OPEN Health
OPEN Health’s latest partnership with Rare Revolution Magazine
Richard Jones introduces our Head of Health Psychology (Dr Sumira Riaz)
OPEN Health CSR Report 2019
Margot Hannah, Partner and Group Managing Director, and CSR lead at OPEN Health shares her thoughts on our latest report.
OPEN Health at ECRD 2020
Gavin Jones shares his thoughts on why congress is so important at this time and the key sessions he is looking forward to.
OPEN Health discuss Global Community in Rare Disease
Annie Rankin how we can work smarter with healthcare professionals
OPEN Health Patient & Brand Communications highly commended finalist
Shortlisted for Best Patient-Centric Approach for 2020 BOBI Awards.
Succeeding with Star Wars Medicine
OPEN Health have published a new white paper demonstrating their commitment to leading the conversation on how effective healthcare communications, and tools that enable them, can lead to faster and...
Three steps I take for stress-free, successful virtual meetings and events
Stacey Osafo, Senior Account Manager, talks about some practical steps she uses for successful virtual meetings and events based on OPEN Health’s vast experience
OPEN Conversations – a webinar series with OPEN Health
OPEN Conversations is a webinar series where experts from OPEN Health answer your questions on pertinent topics in healthcare communications. Available live and on-demand, you can now catch up on...
COVID-19 message to clients from OPEN Health CEO, David Rowley
Dear OPEN Health Clients,I want to highlight to our clients what we’re doing in response to the Coronavirus outbreak to protect our staff, our clients and the community.We’re following the...
The field team are off the road! What should they do next?
Written by Briony Frost , OPEN Health